Avalo Therapeutics (AVTX) Change in Receivables (2017 - 2023)
Avalo Therapeutics (AVTX) posted Change in Receivables of -$38000.0 for Q3 2023, down 200.0% on a QoQ basis from $38000.0 in Q2 2023, and up 93.01% year-over-year from -$19687.6 in Q3 2022.
Avalo Therapeutics (AVTX) Change in Receivables (2017 - 2023) Analysis & Trends
Avalo Therapeutics' Change in Receivables history runs 7 years deep, the most recent figure standing at -$38000.0 for Q3 2023.
- Quarterly Change in Receivables rose 93.01% year-over-year to -$38000.0 in Q3 2023, while the trailing twelve-month figure through Jun 2023 was -$506000.0 (up 85.85% YoY) and the FY2022 annual result came in at -$1.1 million, up 5.1% from the prior year.
- Change in Receivables was -$38000.0 for Q3 2023 at Avalo Therapeutics, down from $38000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $2.1 million in Q3 2019 and bottomed at -$3.5 million in Q4 2019.
- A 5-year average of -$185725.5 and a median of -$123000.0 in 2022 frame the typical range for Change in Receivables.
- Peak annual rise in Change in Receivables reached 798.99% in 2019, while the deepest fall reached 2419.57% in 2019.
- Avalo Therapeutics' Change in Receivables stood at -$3.5 million in 2019, then surged by 114.64% to $506000.0 in 2020, then tumbled by 174.11% to -$375000.0 in 2021, then sank by 45.07% to -$544000.0 in 2022, then soared by 93.01% to -$38000.0 in 2023.
- Business Quant data shows AVTX's Change in Receivables at -$38000.0 in Q3 2023, $38000.0 in Q2 2023, and -$544000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -38,000.00 |
| Sep 30, 2023 | -38,000.00 |
| Jun 30, 2023 | 38,000.00 |
| Jun 30, 2023 | 38,000.00 |
| Sep 30, 2022 | -544,000.00 |
| Sep 30, 2022 | -544,000.00 |
| Jun 30, 2022 | -393,000.00 |
| Jun 30, 2022 | -393,000.00 |
| Mar 31, 2022 | -123,000.00 |
| Mar 31, 2022 | -123,000.00 |
| Dec 31, 2021 | -375,000.00 |
| Dec 31, 2021 | -375,000.00 |
| Sep 30, 2021 | -2.69 Mn |
| Sep 30, 2021 | -2.69 Mn |
| Jun 30, 2021 | 990,000.00 |
| Jun 30, 2021 | 990,000.00 |
| Mar 31, 2021 | 953,000.00 |
| Mar 31, 2021 | 953,000.00 |
| Dec 31, 2020 | 506,000.00 |
| Dec 31, 2020 | 506,000.00 |